It was also confirmed in clinic that BRCA1 mutations or alterations in BRCA1 mRNA and protein expression switch the response to cisplatin- or paclitaxel-based chemotherapy as well as influence the survivals in a number of malignancies, including breast cancer [23], [24], ovarian cancer [25]–[27], gastric cancer [28]–[30] and lung cancer [16], [31]. This evidence concerns the gene BRCA1 and ovarian carcinoma.